Meeting
2014 ASCO Annual Meeting
Phase I/II study of neoadjuvant eribulin mesylate, carboplatin, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
Authors
Lee Steven Schwartzberg
The West Clinic and ACORN Research, LLC, Memphis, TN
Lee Steven Schwartzberg , Kurt W. Tauer , Robert C. Hermann , Petros G. Nikolinakos , Arthur C. Houts
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT01388647
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 604^)
DOI
10.1200/jco.2014.32.15_suppl.604
Abstract #
604^
Poster Bd #
68
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
First Author: Lee Steven Schwartzberg
Poster
2021 ASCO Annual Meeting
Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial.
First Author: Xiaowen Ding
Poster
2021 ASCO Annual Meeting
Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.
First Author: Sayeh Moazami Lavasani
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.
First Author: Hong-Fei Gao